Cresco Labs (CRLBF) EBITDA (2019 - 2026)

Cresco Labs' EBITDA history runs 8 years deep, the most recent figure standing at $11.2 million for Q1 2026.

• Quarterly EBITDA fell 17.78% year-over-year to $11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.4 million (down 133.15% YoY) and the FY2025 annual result came in at -$28.0 million, down 126.08% from the prior year.
• EBITDA was $11.2 million for Q1 2026 at Cresco Labs, up from -$75.5 million in the prior quarter.
• Across five years, EBITDA topped out at $50.7 million in Q1 2022 and bottomed at -$107.8 million in Q3 2023.
• A 5-year average of $8.7 million and a median of $19.4 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2024 — EBITDA surged 713.25% — and 2025, when it tumbled 489.29%.
• Cresco Labs' EBITDA stood at $30.5 million in 2022, then declined by 11.24% to $27.1 million in 2023, then declined by 28.39% to $19.4 million in 2024, then tumbled by 489.29% to -$75.5 million in 2025, then jumped by 114.79% to $11.2 million in 2026.
• Business Quant data shows CRLBF's EBITDA at $11.2 million in Q1 2026, -$75.5 million in Q4 2025, and $17.8 million in Q3 2025.